Prof. Tymianski is a Senior Scientist at the Krembil Brain Institute. Among his scientific contributions is the discovery and development of PSD95 inhibitors for the treatment of stroke and related neurological disorders. His research spans from protein chemistry to global clinical trials. A lead compound, nerinetide, has completed Phase 3 trials and continues to be developed. Next generation compounds are also entering clinical studies. He is a retired neurosurgeon, having treated patients with complex cerebrovascular disorders, and leads NoNO Inc., a biotechnology company that sponsors the development of PSD95 inhibitors.